Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Adjunctive Dulaglutide in Relapsing–Remitting Multiple Sclerosis: A Randomized Open-Label Proof-of-Concept Trial
Saved in:
| Published in: | Neurology and Therapy |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
Similar Items: Adjunctive Dulaglutide in Relapsing–Remitting Multiple Sclerosis: A Randomized Open-Label Proof-of-Concept Trial
- Autoinjectors for Administering Glatiramer Acetate in Relapsing Remitting Multiple Sclerosis in Europe: A Survey of Patient and Nurse Preferences
- A Qualitative Study of Lived Treatment Experiences and Preferences of Long-Term DMT Users with Relapsing–Remitting Multiple Sclerosis
- Summary of Research: Cognition and Employment Status of People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two-Year CLARIFY-MS Study
- Correction: Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two‑year Phase IV CLARIFY‑MS Study
- Social Cognition in Multiple Sclerosis: A Multidomain Investigation
- Dynamic Triangulation of Resting-State Networks and CSF Metabolites Reveals Bidirectional Causal Pathways in Multiple Sclerosis: A Mendelian Randomization Analysis